Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment
Davida F Kruger,1 Susan LaRue,2,3 Phil Estepa31Henry Ford Health System, Detroit, MI, USA; 2Amylin Pharmaceuticals, San Diego, CA, USA; 3AstraZeneca, San Diego, CA, USAAbstract: Injectable treatments, such as glucagon-like peptide-1 receptor agonists and insulin, are options for the pharmacologic t...
Guardado en:
Autores principales: | Kruger DF, LaRue S, Estepa P |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c4101dd3e397480987d143c0013dfd54 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Guidelines in the management of diabetic nerve pain clinical utility of pregabalin
por: Vinik AI, et al.
Publicado: (2013) -
Maintaining efficacy in the treatment of diabetic peripheral neuropathic pain: role of duloxetine
por: Lindsay Zilliox, et al.
Publicado: (2010) -
Association of patient-rated severity with other outcomes in patients with painful diabetic peripheral neuropathy
por: Taylor-Stokes G, et al.
Publicado: (2011) -
Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey
por: Sadosky A, et al.
Publicado: (2013) -
Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
por: Hinnen D, et al.
Publicado: (2019)